Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
Clinical trial NCT01214239 · COMPLETED
Trial details
- NCT number
- NCT01214239
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2010-10-01
- Primary completion
- 2012-05-01
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.